- Home
- EQT vs GMAB Comparison
EQT vs GMAB Comparison
Compare EQT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQT
- GMAB
- Stock Information
- Founded
- EQT 1925
- GMAB 1999
- Country
- EQT United States
- GMAB Denmark
- Employees
- EQT N/A
- GMAB N/A
- Industry
- EQT Oil & Gas Production
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EQT Energy
- GMAB Health Care
- Exchange
- EQT Nasdaq
- GMAB Nasdaq
- Market Cap
- EQT 15.7B
- GMAB 15.0B
- IPO Year
- EQT N/A
- GMAB N/A
- Fundamental
- Price
- EQT $45.92
- GMAB $20.65
- Analyst Decision
- EQT Buy
- GMAB Buy
- Analyst Count
- EQT 18
- GMAB 8
- Target Price
- EQT $42.12
- GMAB $43.00
- AVG Volume (30 Days)
- EQT 8.1M
- GMAB 1.4M
- Earning Date
- EQT 10-29-2024
- GMAB 11-06-2024
- Dividend Yield
- EQT 1.39%
- GMAB N/A
- EPS Growth
- EQT N/A
- GMAB 14.35
- EPS
- EQT 0.67
- GMAB 10.80
- Revenue
- EQT $4,623,048,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- EQT $14.73
- GMAB $30.31
- Revenue Next Year
- EQT $33.78
- GMAB $16.49
- P/E Ratio
- EQT $68.57
- GMAB $18.68
- Revenue Growth
- EQT N/A
- GMAB 17.75
- 52 Week Low
- EQT $30.02
- GMAB $20.34
- 52 Week High
- EQT $48.02
- GMAB $32.88
- Technical
- Relative Strength Index (RSI)
- EQT 71.23
- GMAB 29.22
- Support Level
- EQT $42.38
- GMAB $20.34
- Resistance Level
- EQT $48.02
- GMAB $23.47
- Average True Range (ATR)
- EQT 1.39
- GMAB 0.46
- MACD
- EQT 0.45
- GMAB -0.12
- Stochastic Oscillator
- EQT 81.33
- GMAB 9.90
About EQT EQT Corporation
EQT Corp is an independent natural gas production company with operations focused in the cores of the Marcellus and Utica shales in the Appalachian Basin, located in the Eastern United States. The firm focuses on executing combo-development projects for developing multiwell pads to meet supply needs, with a focus on maximizing operational efficiency, technology, and sustainability. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has one reportable segment and its revenue stems from three types of gas reserves: natural gas, natural gas liquids, and crude oil. All of the firm's operating revenue is generated in the U.S., with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.